Compare Arm Holdings plc (ARM) vs Danaher Corporation (DHR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Arm Holdings plc vs Danaher Corporation — how do they compare? Arm Holdings plc trades at $315.46 (market cap $345.41B), while Danaher Corporation trades at $200 (market cap $140.88B). The key difference: Arm Holdings plc is far larger — about 2.5× Danaher Corporation's market cap, and Danaher Corporation pays a 0.8% dividend while Arm Holdings plc pays none. Which is the better fit depends on your goals.
| ARM | DHR | |
|---|---|---|
Market Cap | $345.41B | $140.88B |
Sector | Technology | Health |
52-Week High | $439.46 | $242.05 |
52-Week Low | $104.55 | $161.91 |
Enterprise Value | $342.26B | $153.66B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARM Holdings trades at $323.39, down 1.37% over 24 hours, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The company reported robust revenue growth to $4.01B in 2025, with net income of $792M, though valuation ratios like P/E of 380.46 reflect premium pricing. Recent news highlights ARM's role in AI infrastructure and data center expansion, driving investor optimism.
Outlook remains positive with analyst consensus favoring buy ratings (74.07%) and a $321.65 price target, but risks include high valuation sensitivity and competitive pressures in the semiconductor space. Upside potential hinges on continued AI-driven demand and execution of growth initiatives like the AGI CPU launch.
Danaher (DHR) trades at $199.05, up 1.57% today, with strong technical momentum as price approaches resistance at $200. The company demonstrates consistent earnings beats with Q1 2026 EPS of $2.06 exceeding expectations of $1.94, though revenue growth remains modest at 2.9% year-over-year. Recent developments include the Masimo acquisition approval and new product launches in the biotechnology segment, supporting positive analyst sentiment.
DHR presents a mixed outlook with strong analyst support (69% buy ratings) and a $214.73 consensus target offering 7.9% upside, but faces risks from elevated valuation (P/E 38.58) and slowing profit margins. The stock's near-term direction will depend on Q2 2026 earnings delivery and biotechnology segment performance amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arm Holdings plc
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
